This company has been acquired
F-star Therapeutics Dirección
Dirección controles de criterios 2/4
Información clave
Eliot Forster
Chief Executive Officer (CEO)
US$2.8m
Compensación total
| Porcentaje del salario del CEO | 23.7% |
| Permanencia del CEO | 2.3yrs |
| Participación del CEO | 1.3% |
| Permanencia media de la dirección | 2.3yrs |
| Promedio de permanencia en la Junta Directiva | 2.8yrs |
Actualizaciones recientes de la dirección
Recent updates
F-star Therapeutics: Running Into A National Security Roadblock
Sep 22F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale
Sep 15F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Jul 29F-star enters license deal with Takeda for a cancer immune therapy antibody
Jul 20Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues
May 18
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results
Mar 17These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts
Mar 16F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
Jan 27F-star Therapeutics under pressure on pricing $65M stock offering
May 07Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like
Mar 17Merck KGaA discloses 5.4% stake in F-star Therapeutics
Feb 02Dosing underway in early-stage study of F-star's FS120 in cancer
Dec 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$45m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$3m | US$665k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$37m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | US$5m | US$645k | -US$26m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$24m |
| Dec 31 2019 | US$2m | US$436k | -US$23m |
Compensación vs. Mercado: Eliot's total compensation ($USD2.80M) is above average for companies of similar size in the US market ($USD1.69M).
Compensación vs. Ingresos: Eliot's compensation has been consistent with company performance over the past year.
CEO
Eliot Forster (56 yo)
2.3yrs
Permanencia
US$2,801,895
Compensación
Dr. Eliot Richard Forster, Ph D, MBA, serves as CEO and President at F-star Therapeutics, Inc. since, November 20, 2020 and serves as its Director. Dr. Forster served as Interim Supervisory Director at Imm...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.3yrs | US$2.80m | 1.27% $ 2.0m | |
| CFO, Treasurer & Secretary | 3.8yrs | US$1.14m | 0% $ 0 | |
| Chief Scientific Officer | no data | US$838.42k | 0.44% $ 686.8k | |
| Chief Medical Officer | 2.3yrs | US$933.66k | 0% $ 0 | |
| Vice President of Investor Relations & Communications | no data | sin datos | sin datos | |
| Chief Development Officer | less than a year | sin datos | sin datos |
2.3yrs
Permanencia media
60yo
Promedio de edad
Equipo directivo experimentado: FSTX's management team is considered experienced (2.3 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | no data | US$2.80m | 1.27% $ 2.0m | |
| Independent Director | 2.3yrs | US$155.10k | 0.068% $ 106.8k | |
| Independent Director | 3.3yrs | US$167.94k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$184.68k | 0% $ 0 | |
| Independent Chairman | 3.8yrs | US$1.02m | 0% $ 0 | |
| Independent Director | 2.3yrs | US$170.10k | 0.043% $ 67.5k | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Independent Director | 2.3yrs | US$151.60k | 0% $ 0 | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos |
2.8yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: FSTX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.